X

Trial Profile

A multicenter, prospective, observational study of CT-P13

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 28 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Infliximab (Primary)
Indications Ankylosing spondylitis; Axial spondyloarthritis; Crohn's disease; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
Focus Adverse reactions; Therapeutic Use
Acronyms Reflect
Sponsors Pfizer

Most Recent Events

14 Nov 2022 Final results of 2 years of follow-up (n=1,400) presented at the ACR Convergence 2022.
06 Jun 2020 Results of 18-months follow-up of patients with rheumatic diseases (n=616; as of Jan 2019) presented at the 21st Annual Congress of the European League Against Rheumatism
20 Dec 2018 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com